ProteoSys AG
🇩🇪Germany
Clinical Trials
1
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
- Conditions
- Prostate CancerBenign Prostatic HyperplasiaProstatic Intraepithelial Neoplasia
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2007-02-05
- Lead Sponsor
- ProteoSys AG
- Target Recruit Count
- 750
- Registration Number
- NCT00400894
News
No news found